• <table id="gigg0"></table>
  • west china medical publishers
    Author
    • Title
    • Author
    • Keyword
    • Abstract
    Advance search
    Advance search

    Search

    find Author "MA Jianxin" 3 results
    • Investigation of Clinical Practice and Side Effects of Shenfu Injection

      Objective To investigate the status of clinical practices and side effects related to Shenfu injection.Method We searched the China National Knowledge Infrastructure (CNKI) database using the key word “Shenfuinjection”. Original clinical studies of Shenfu injection which were published from January 1993 to December 2008 inChinese magazines were included. Results A total of 576 relevant clinical studies were identified. There were 21 496 cases in the study group and excluding the control group patients. We investigated and analyzed the side effects of Shenfu injection. For cases with side effects, the medication dosage, the diseases for treatment, the method of medication, the menstruum, and course of treatment for the side effects were evaluated. All the side effects were mild except one case of anaphylactic shock. Conclusion Shenfu injection has been widely used in clinical patients since it came into the market in 1993. However, systematic evaluation of its clinical application is lacking, and there are some unsolved problems and deficiency in selecting and expanding diseases for treatment, evaluating the dosage and treatment method, and investigating the side effects of the drug. Therefore, it is imperative to enhance the evaluation drugs and good clinical application after the drugs come into the market with evidence-based medicine.

      Release date:2016-09-07 02:09 Export PDF Favorites Scan
    • Clinic Trial of Lidanqing Pellets in Treating Chronic Cholecystitis with Damp and Hot Accumulate Knot Including Blood Stasisso

      【摘要】 目的 觀察利膽清微丸治療慢性膽囊炎濕熱蘊結兼血瘀證患者的療效及安全性,進一步為臨床研究提供依據。 方法 2001年4—7月,采用雙盲、雙模擬、隨機平行對照臨床試驗,將40例患者隨機分為試驗組(20例)及對照組(20例)。試驗組服用利膽清微丸3.5 g/次,3次/d,同時服用膽寧片模擬劑;對照組服用膽寧片3片/次,3次/d,同時服用利膽清微丸模擬劑。 結果 試驗組痊愈1例,顯效12例,有效5例,無效2例,顯效率65%,有效率90%;對照組痊愈2例,顯效10例,有效7例,無效1例,顯效率60%,有效率95%,兩組療效比較差異無統計學意義(Pgt;0.05)。試驗過程中未發現明顯不良反應。 結論 利膽清微丸對于治療慢性膽囊炎濕熱蘊結兼血瘀證有良好效果,是一種安全有效的藥物。【Abstract】 Objective To observe the safety and efficacy of Lidanqing pellet on chronic cholecystitis with damp and hot accumulate knot including blood stasis, and to provide a basis for further clinical trials.  Methods A double-blind, double dummy, randomized, and controlled clinic trial was undertaken between April and July 2001. A total of 40 patients were randomly divided into trail group and control group. The trial group was given Lidanqin pellet 3.5 g per time, and three times per day; simultaneously taking Danning tablet simulation agent. The control group was given 3 tablets of Danning tablet per time and three times per day; simultaneously taking taking Lidanqing pellets simulation agent.  Results In the trail group, one patient was cured, the therapeutic effect was obvious in 12, basically effective in five and invalid in two (with the rate of obvious effect of 65.00% and rate of basic effect of 90.00%). In the control group, two patients was cured, the therapeutic effect was obvious in 12, basically effective in 10, effective in seven and invalid in one (with the rate of basic effect of 60.00% and the rate of obvious effect of 95.00%). The difference between the two groups was significant (Pgt;0.05). Adverse reaction was not found in the trial group.  Conclusion Lidanqing pellet, a safe medication, is effective on chronic cholecystitis with damp and hot accumulate knot including blood stasis.

      Release date:2016-09-08 09:26 Export PDF Favorites Scan
    • Assessment of Systematic Reviews and Meta-analyses on Traditional Chinese Medicine Published in Chinese Journals

      Objective To assess the quality of published systematic reviews and meta-analyses on Traditional Chinese Medicine (TCM) published in Chinese journals. Methods We searched CNKI, CMB from January 1995 to December 2006 and The Cochrane Library (Issue 4, 2006) for systematic reviews and meta-analyses on TCM. We extracted details of the interventions used in the treatment and control groups, analyzed the validity of included studies and investigated whether the reports used QUOROM statement or not. Results We identified 111 reports, of which 1 on prevention, 1 on adverse events, 1 on risk factors and premonitory symptoms, 2 on physiochemical parameters, and 106 on effectiveness and safety assessment. In total, 42 types of diseases were involved, and 41 reports were related to cerebrovascular diseases. As for the investigated interventions, 25 studies assessed TCM and 12 assessed acupuncture. Two had no control intervention design control in the group, 15 did not describe the interventions in the control group, 50 used active control (26 for western medicine, 12 for Chinese medicine, 12 for western plus Chinese medicine), 14 used blank control, 17 used baseline control, 4 used sham acupuncture or acupoint injection control etc., 5 used placebo control and 4 used "mutual control". The interventions used in the treatment and control groups varied widely. The number of trials included in the reviews and meta-analyses ranged from 1 to 35, and 24 studies included non-randomized controlled trials. Of the 111 reports, 14 were Cochrane reviews, 16 did not assess the quality of included randomized trials and a further 22 performed only simple and nonstandard quality assessment of the included trials. None of the reviews or meta-analyses used the QUOROM statement to report their results. Conclusions Because of the unique characteristics of TCM, systematic reviews of TCM should focus on a specific topic, avoid the selection of too many drugs, address the target indications of the test drugs and pay attention on intervention evaluation. High quality systematic reviews of TCM are needed but they will only be produced through the concerted efforts of clinicians, TCM practitioners and methodologists.

      Release date:2016-09-07 02:15 Export PDF Favorites Scan
    1 pages Previous 1 Next

    Format

    Content

  • <table id="gigg0"></table>
  • 松坂南